<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
Commission File Number 1-11150
------------
(Check One):
[X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR
For Period Ended: MARCH 31, 1998
--------------------------------------------------------
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:
-----------------------------------------
- ------------------------------------------------------------------------------
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
- ------------------------------------------------------------------------------
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
- ------------------------------------------------------------------------------
PART I -- REGISTRANT INFORMATION
IMAGYN MEDICAL TECHNOLOGIES INC.
- ------------------------------------------------------------------------------
Full Name of Registrant
- ------------------------------------------------------------------------------
Former Name if Applicable
5 CIVIC PLAZA, SUITE 100
- ------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)
NEWPORT BEACH, CA 92660
- ------------------------------------------------------------------------------
City, State and Zip Code
PART II -- RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rules 12b-25(b), the following
should be completed. (Check box if appropriate)
[X] (a) The reasons described in reasonable detail in
Part III of this form could not be eliminated
without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual
report, transition report on Form 10-K, Form
20-F, 11-K, Form N-SAR, or portion thereof,
will be filed on or before the fifteenth
calendar day following the prescribed due
date; or the subject quarterly report of
transition report on Form 10-Q, or portion
thereof will be filed on or before the fifth
calendar day following the prescribed due
date; and
[X] (c) The accountant's statement or other exhibit
required by Rule 12b-25(c) has been attached
if applicable.
<PAGE> 2
PART III--NARRATIVE
State below in reasonable detail the reasons why the Form 10-K, 20-F, 11-K,
10-Q, N-SAR, or the transition report or portion thereof, could not be filed
within the prescribed time period. (ATTACH EXTRA SHEETS IF NEEDED)
See Exhibit 1
PART IV--OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to
this notification
<TABLE>
<S> <C> <C>
MICHAEL L. HAWKINS 949 668-5858
--------------------------------------- ----------- ------------------
(Name) (Area Code) (Telephone Number)
</TABLE>
(2) Have all other periodic reports required under Section 13 or
15(d) of the Securities Exchange Act of 1934 or Section 30 of
the Investment Company Act of 1940 during the preceding 12
months or for such shorter period that the registrant was
required to file such report(s) been filed? If answer is no,
identify report(s).
[X] Yes [ ] No
------------------------------------------------
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal
year will be reflected by the earnings statements to be
included in the subject report of portion thereof?
[ ] Yes [X] No
If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of the results cannot be
made.
- ------------------------------------------------------------------------------
IMAGYN MEDICAL TECHNOLOGIES, INC.
--------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date JUNE 30, 1998 By /s/ CHARLES A. LAVERTY
--------------------------- -------------------------------------
CHARLES A. LAVERTY
CHIEF EXECUTIVE OFFICER
INSTRUCTION: The form may be signed by an executive officer of the registrant
or by any other duly authorized representative. The name and title of the
person signing the form shall be typed or printed beneath the signature. If
the statement is signed on behalf of the registrant by an authorized
representative (other than an executive officer), evidence of the
representative's authority to sign on behalf of the registrant shall be filed
with the form.
ATTENTION
- ------------------------------------------------------------------------------
Intentional misstatements or omissions of fact constitute Federal Criminal
Violations (See 18 U.S.C. 1001)
- ------------------------------------------------------------------------------
(Attach Extra Sheets If Needed)
<PAGE> 3
Exhibit 1
to
Form 12b-25
of Imagyn Medical Technologies, Inc.
dated June 30, 1998
As previously reported in a Current Report on Form 8-K, filed with the
Securities and Exchange Commission on March 5, 1998, the Company elected to
change its independent auditors, and in connection with that change Deloitte &
Touche LLP was appointed as new independent auditors for the Company.
As a result of the change in auditors, the completion of the audit for the
year ended March 31, 1998 is taking longer to complete than originally planned,
and thus the preparation and finalizing of the Company's Annual Report on Form
10-K has been delayed. This delay could not have been eliminated without
unreasonable effort or expense. The Company intends to file with the Securities
and Exchange Commission the Annual Report on Form 10-K for the year ended March
31, 1998 on or before the fifteenth calendar day after the due date for the
Annual Report on Form 10-K.
<PAGE> 1
EXHIBIT 99.1
June 30, 1998
Securities & Exchange Commission
Mail Stop 9-5
450 5th Street, N.W.
Washington, D.C. 20549
Ladies and Gentlemen:
We have read and agree with the comments in Part III of Form 12b-25 of Imagyn
Medical Technologies, Inc. for the fiscal year ended March 31, 1998, dated on
June 30, 1998.
Yours truly,
/s/ DELOITTE & TOUCHE LLP
Costa Mesa, CA
